Compare CENN & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENN | ENVB |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.1M |
| IPO Year | 2017 | 2000 |
| Metric | CENN | ENVB |
|---|---|---|
| Price | $3.95 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 126.4K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $18,080,161.00 | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.07 | $0.56 |
| 52 Week High | $4.73 | $13.25 |
| Indicator | CENN | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 29.60 |
| Support Level | $0.14 | $0.58 |
| Resistance Level | $4.60 | $2.13 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 49.35 | 10.59 |
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, iChassis, Avantier, Teemak, Bison Motor, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the Europe, and also has a presence in America, Asia, and other regions.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.